Published in J Virol on November 01, 1996
Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med (1998) 2.72
Immunity to retroviral infection: the Friend virus model. Proc Natl Acad Sci U S A (1997) 2.28
Immunosuppression by CD4+ regulatory T cells induced by chronic retroviral infection. Proc Natl Acad Sci U S A (2001) 2.04
CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J Exp Med (2002) 1.53
Suppression of acute anti-friend virus CD8+ T-cell responses by coinfection with lactate dehydrogenase-elevating virus. J Virol (2007) 1.50
PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing. PLoS Pathog (2015) 1.49
Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8+ T cells and reduces chronic retroviral set points. Proc Natl Acad Sci U S A (2011) 1.26
CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection. J Virol (2005) 1.26
Virus-specific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication. J Immunol (2011) 1.23
Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. Proc Natl Acad Sci U S A (2004) 1.20
Characterization of glycosylated Gag expressed by a neurovirulent murine leukemia virus: identification of differences in processing in vitro and in vivo. J Virol (1997) 1.20
Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses. Proc Natl Acad Sci U S A (2010) 1.18
Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28. J Exp Med (2000) 1.15
The level of friend retrovirus replication determines the cytolytic pathway of CD8+ T-cell-mediated pathogen control. J Virol (2007) 1.10
Role of natural killer cells in resistance against friend retrovirus-induced leukemia. J Virol (2001) 1.08
Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific CD8+ T cells and efficiently reduces chronic retroviral loads. PLoS Pathog (2013) 1.08
CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells. J Immunol (2008) 1.05
Effects of acute and chronic murine norovirus infections on immune responses and recovery from Friend retrovirus infection. J Virol (2009) 1.04
Temporal effects of gamma interferon deficiency on the course of Friend retrovirus infection in mice. J Virol (2002) 1.01
Reduction of retrovirus-induced immunosuppression by in vivo modulation of T cells during acute infection. J Virol (2004) 0.99
Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. Cancer Res (2012) 0.98
Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection. PLoS Pathog (2012) 0.97
Negative selection by an endogenous retrovirus promotes a higher-avidity CD4+ T cell response to retroviral infection. PLoS Pathog (2012) 0.95
Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors. J Virol (2001) 0.93
A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog (2010) 0.92
Age-dependent tolerance to an endogenous tumor-associated antigen. Vaccine (2008) 0.92
Dissecting the immune response to moloney murine sarcoma/leukemia virus-induced tumors by means of a DNA vaccination approach. J Virol (1999) 0.90
Tetherin promotes the innate and adaptive cell-mediated immune response against retrovirus infection in vivo. J Immunol (2014) 0.90
Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. Retrovirology (2011) 0.90
Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. J Virol (2002) 0.87
Codelivery of the chemokine CCL3 by an adenovirus-based vaccine improves protection from retrovirus infection. J Virol (2011) 0.86
IL-2-independent and TNF-α-dependent expansion of Vβ5+ natural regulatory T cells during retrovirus infection. J Immunol (2013) 0.86
Identification of a protective CD4+ T-cell epitope in p15gag of Friend murine leukemia virus and role of the MA protein targeting the plasma membrane in immunogenicity. J Virol (2004) 0.86
Negative impact of IFN-γ on early host immune responses to retroviral infection. J Immunol (2012) 0.85
Complement as an endogenous adjuvant for dendritic cell-mediated induction of retrovirus-specific CTLs. PLoS Pathog (2010) 0.84
Tumor-specific CD4+ T cells develop cytotoxic activity and eliminate virus-induced tumor cells in the absence of regulatory T cells. Cancer Immunol Immunother (2012) 0.84
Complement opsonization enhances friend virus infection of B cells and thereby amplifies the virus-specific CD8+ T cell response. J Virol (2010) 0.83
NK cells improve control of friend virus infection in mice persistently infected with murine cytomegalovirus. Retrovirology (2013) 0.83
Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation. Blood (2013) 0.83
Inflammation programs self-reactive CD8+ T cells to acquire T-box-mediated effector function but does not prevent deletional tolerance. J Leukoc Biol (2014) 0.82
Mice of the resistant H-2(b) haplotype mount broad CD4(+) T cell responses against 9 distinct Friend virus epitopes. Virology (2014) 0.82
Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen. Blood (2008) 0.82
Activated CD8+ T cells induce expansion of Vβ5+ regulatory T cells via TNFR2 signaling. J Immunol (2014) 0.80
Modification of one epitope-flanking amino acid allows for the induction of friend retrovirus-specific CD8+ T cells by Adenovirus-based immunization. J Virol (2012) 0.80
Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice. J Virol (2007) 0.80
DNA fusion gene vaccination mobilizes effective anti-leukemic cytotoxic T lymphocytes from a tolerized repertoire. Eur J Immunol (2008) 0.80
Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody. J Virol (2010) 0.80
Targeting viral antigens to CD11c on dendritic cells induces retrovirus-specific T cell responses. PLoS One (2012) 0.78
Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery. Retrovirology (2017) 0.76
Inducible epithelial resistance protects mice against leukemia-associated pneumonia. Blood (2016) 0.76
Hierarchal utilization of different T-cell receptor Vbeta gene segments in the CD8(+)-T-cell response to an immunodominant Moloney leukemia virus-encoded epitope in vivo. J Virol (1999) 0.76
Dichotomy between T Cell and B Cell Tolerance to Neonatal Retroviral Infection Permits T Cell Therapy. J Immunol (2016) 0.75
Interference of retroviral envelope with vaccine-induced CD8(+) T cell responses is relieved by co-administration of cytokine-encoding vectors. Retrovirology (2017) 0.75
Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation. Oncoimmunology (2015) 0.75
Immunodominance of adenovirus-derived CD8(+) T cell epitopes interferes with the induction of transgene-specific immunity in adenovirus-based immunization. J Virol (2017) 0.75
B Cell Requirement for Robust Regulatory T Cell Responses to Friend Retrovirus Infection. MBio (2017) 0.75
The dose of retroviral infection determines the induction of anti-viral NK cell responses. J Virol (2017) 0.75
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (1991) 13.90
Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature (1989) 7.11
Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature (1990) 6.23
Empty MHC class I molecules come out in the cold. Nature (1990) 5.53
Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A (1983) 4.69
Characterization of monoclonal antibodies reactive with murine leukemia viruses: use in analysis of strains of friend MCF and Friend ecotropic murine leukemia virus. Virology (1983) 4.16
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med (1992) 4.11
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med (1992) 3.75
Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology (1981) 3.61
Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol (1991) 3.58
CUG initiation codon used for the synthesis of a cell surface antigen coded by the murine leukemia virus. J Mol Biol (1989) 3.56
Exact prediction of a natural T cell epitope. Eur J Immunol (1991) 2.90
Generation, translocation, and presentation of MHC class I-restricted peptides. Annu Rev Biochem (1995) 2.76
Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol (1980) 2.20
T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science (1986) 2.06
Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells. J Immunol (1975) 2.06
Studies on the role of the host immune response in recovery from Friend virus leukemia. II. Cell-mediated immunity. J Exp Med (1976) 1.90
A nonstructural gag-encoded glycoprotein precursor is necessary for efficient spreading and pathogenesis of murine leukemia viruses. J Virol (1994) 1.64
Immunity to oncogenic proteins. Immunol Rev (1995) 1.58
Role and specificity of T-cell subsets in spontaneous recovery from Friend virus-induced leukemia in mice. J Virol (1992) 1.55
Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol (1993) 1.51
Friend virus-specific cytotoxic T lymphocytes recognize both gag and env gene-encoded specificities. J Exp Med (1986) 1.50
Cross-resistance to the transplantation of syngeneic Friend, Moloney, and Rauscher virus-induced tumors. Cancer Res (1968) 1.39
Specificity of 51Cr-release cytotoxicity of lymphocytes immune to murine sarcoma virus. J Natl Cancer Inst (1974) 1.38
Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells. J Virol (1993) 1.36
Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. J Virol (1992) 1.33
Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness. Proc Natl Acad Sci U S A (1995) 1.33
Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J Immunol (1993) 1.32
FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens. J Exp Med (1989) 1.25
Fine structure of a virus-encoded helper T-cell epitope expressed on FBL-3 tumor cells. J Virol (1994) 1.06
Identification of an epitope encoded in the env gene of Friend murine leukemia virus recognized by anti-Friend virus cytotoxic T lymphocytes. Virology (1991) 1.04
A single retroviral gag precursor signal peptide recognized by FBL-3 tumor-specific cytotoxic T lymphocytes. J Virol (1995) 0.97
Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. Mol Immunol (1994) 0.94
Adoptively transferred antigen-specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2. J Immunol (1990) 0.86
MHC class I-restricted processing of transmembrane proteins. Mechanism and biologic significance. J Immunol (1995) 0.85
Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides. Ciba Found Symp (1994) 0.80
DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae. Nature (2000) 19.93
Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science (2000) 16.04
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
Genome sequence of the radioresistant bacterium Deinococcus radiodurans R1. Science (1999) 8.01
Cell-free formation of protease-resistant prion protein. Nature (1994) 6.07
Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother (1990) 4.51
Affinity labeling of a phosphorylcholine binding mouse myeloma protein. Biochemistry (1972) 4.26
Characterization of monoclonal antibodies reactive with murine leukemia viruses: use in analysis of strains of friend MCF and Friend ecotropic murine leukemia virus. Virology (1983) 4.16
Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology (1981) 3.61
Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol (1997) 3.44
Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature (1985) 3.38
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex. J Exp Med (1974) 2.89
Hemolytic anemia and erythroleukemia, two distinct pathogenic effects of Friend MuLV: mapping of the effects to different regions of the viral genome. Cell (1986) 2.69
Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med (1985) 2.65
p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. Methods (1997) 2.65
Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A (1995) 2.58
Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread. Virology (1995) 2.55
Characterization of scrapie infection in mouse neuroblastoma cells. J Gen Virol (1987) 2.54
Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol (1994) 2.51
Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med (1981) 2.50
Different murine cell lines manifest unique patterns of interference to superinfection by murine leukemia viruses. Virology (1985) 2.44
Prion protein and the transmissible spongiform encephalopathies. Trends Cell Biol (1997) 2.39
Scrapie infectivity found in resistant species. Nature (1998) 2.28
Immunity to retroviral infection: the Friend virus model. Proc Natl Acad Sci U S A (1997) 2.28
Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol (1994) 2.21
Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol (1980) 2.20
Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol (1989) 2.08
T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science (1986) 2.06
Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods (1991) 2.01
Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J (2001) 1.95
Aleutian disease of mink: the antibody response of sapphire and pastel mink to Aleutian disease virus. J Immunol (1975) 1.95
Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex. Proc Natl Acad Sci U S A (1979) 1.95
Entry versus blockade of brain infection following oral or intraperitoneal scrapie administration: role of prion protein expression in peripheral nerves and spleen. J Virol (2000) 1.93
Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J Virol (1988) 1.92
Molecular cloning and complete sequence of prion protein cDNA from mouse brain infected with the scrapie agent. Proc Natl Acad Sci U S A (1986) 1.92
Studies on the role of the host immune response in recovery from Friend virus leukemia. II. Cell-mediated immunity. J Exp Med (1976) 1.90
A single hamster PrP amino acid blocks conversion to protease-resistant PrP in scrapie-infected mouse neuroblastoma cells. J Virol (1995) 1.87
Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells. J Virol (1994) 1.85
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol (1997) 1.84
Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine. J Virol (1991) 1.79
Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med (1982) 1.76
Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron (1995) 1.71
Studies on the role of the host immune response in recovery from Friend virus leukemia. I. Antiviral and antileukemia cell antibodies. J Exp Med (1976) 1.69
Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res (1999) 1.68
Rfv-1 and Rfv-2, two H-2-associated genes that influence recovery from Friend leukemia virus-induced splenomegaly. J Immunol (1978) 1.66
Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood (1996) 1.66
The ultrastructure of normal and pathological IgM immunoglobulins. J Exp Med (1968) 1.64
Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J Exp Med (1986) 1.62
Effect of murine host genotype on MCF virus expression, latency, and leukemia cell type of leukemias induced by Friend murine leukemia helper virus. Virology (1983) 1.62
Complete nucleotide sequence of Friend murine leukemia virus, strain FB29. Nucleic Acids Res (1991) 1.61
Role of the host immune response in selection of equine infectious anemia virus variants. J Virol (1987) 1.56
Role and specificity of T-cell subsets in spontaneous recovery from Friend virus-induced leukemia in mice. J Virol (1992) 1.55
Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients. J Virol (1998) 1.52
Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope (2000) 1.51
V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1. J Virol (1999) 1.49
Purification and ultrastructure of Aleutian disease virus of mink. Nature (1975) 1.47
Different H-2 subregions influence immunization against retrovirus and immunosuppression. Nature (1987) 1.43
TP53 codon 72 polymorphism with hepatocellular carcinoma: a metaanalysis. J Int Med Res (2012) 1.43
Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med (1986) 1.41
Characterization of Ia8 antigen, thy-1.2 antigen, complement receptors, and virus production in a group of murine virus-induced leukemia cell lines. J Immunol (1976) 1.41
Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia. J Immunol (1983) 1.38
Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J Immunol (1989) 1.38
Antibody-induced modulation of Friend virus cell surface antigens decreases virus production by persistent erythroleukemia cells: influence of the Rfv-3 gene. Proc Natl Acad Sci U S A (1979) 1.38
Overexpression of human copper, zinc-superoxide dismutase (SOD1) prevents postischemic injury. Proc Natl Acad Sci U S A (1998) 1.37
Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. EMBO J (1997) 1.36
Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J Biol Chem (1998) 1.35
Sequences in the U5-gag-pol region influence early and late pathogenic effects of Friend and Moloney murine leukemia viruses. J Virol (1990) 1.34
Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. Leukemia (2012) 1.34
Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. J Virol (1992) 1.33
Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness. Proc Natl Acad Sci U S A (1995) 1.33
Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence. Curr Top Microbiol Immunol (1995) 1.29
H-2D control of recovery from Friend virus leukemia: H-2D region influences the kinetics of the T lymphocyte response to Friend virus. J Exp Med (1983) 1.28
Detection of prion protein mRNA in normal and scrapie-infected tissues and cell lines. J Gen Virol (1988) 1.28
Change in host cell tropism associated with in vitro replication of equine infectious anemia virus. J Virol (1989) 1.28
Oncogenic proteins as tumor antigens. Curr Opin Immunol (1996) 1.27
TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J Immunol (1997) 1.27
Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2. J Immunol (1981) 1.27
WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia (2003) 1.25
Pseudotyping of dual-tropic recombinant viruses generated by infection of mice with different ecotropic murine leukemia viruses. Virology (1985) 1.25
Normal and scrapie-associated forms of prion protein differ in their sensitivities to phospholipase and proteases in intact neuroblastoma cells. J Virol (1990) 1.24
Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med (1984) 1.24
In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res (1994) 1.20
Leukemia induction by a new strain of Friend mink cell focus-inducing virus: synergistic effect of Friend ecotropic murine leukemia virus. J Virol (1984) 1.19
Chromosome mapping of Rfv3, a host resistance gene to Friend murine retrovirus. J Virol (1995) 1.18
Monoclonal antibodies against Aleutian disease virus distinguish virus strains and differentiate sites of virus replication from sites of viral antigen sequestration. J Virol (1986) 1.18
Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood (2000) 1.18
Characterization of a neurologic disease induced by a polytropic murine retrovirus: evidence for differential targeting of ecotropic and polytropic viruses in the brain. J Virol (1995) 1.18
Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence. J Virol (1999) 1.16
Murine leukemia virus infectious centers are dependent on the rate of virus production by infected cells. Virology (1978) 1.16
IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat (2011) 1.16
Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells. J Immunol (1984) 1.15
Influence of the murine MHC (H-2) on Friend leukemia virus-induced immunosuppression. J Exp Med (1986) 1.15
A 60-kDa prion protein (PrP) with properties of both the normal and scrapie-associated forms of PrP. J Biol Chem (1995) 1.15
The cell tropism of human immunodeficiency virus type 1 determines the kinetics of plasma viremia in SCID mice reconstituted with human peripheral blood leukocytes. J Virol (1998) 1.15
Immunoprotective determinants in friend murine leukemia virus envelope protein. Virology (1998) 1.14
Identification of a hypervariable region in the long terminal repeat of equine infectious anemia virus. J Virol (1991) 1.13